Aspartylglucosaminuria (AGU) is a rare, hereditary lysosomal disease caused by biallelic variants in the AGA gene. Deficiency of the enzyme aspartylglucosaminidase prevents the correct degradation of certain glycoproteins, leading to the accumulation of aspartylglucosamine and other glicoasparagines in lysosomes and progressive neurodegenerative impairment.
Aspartylglucosaminuria
Aspartylglucosaminuria is a progressive neurodegenerative lysosomal disorder included within the lysosomal storage diseases. It is caused by pathogenic variants in the AGA gene, which encodes the enzyme aspartylglucosaminidase. This enzyme acts in the lysosomes, responsible for cellular recycling, and participates in the final step of the degradation of glycoproteins with N-glycans. When enzymatic activity is reduced or absent, glycoasparagins accumulate progressively within the cells, with a particular impact on the central nervous system.
AGU is transmitted in an autosomal recessive pattern, meaning an affected person must inherit two altered copies of the AGA gene, one from each parent. It is a very rare disease worldwide, although it is observed more frequently in the Finnish population due to a founder variant. In Finland, an approximate prevalence of 1.5 to 5 cases per 100,000 live births has been estimated, while in other populations its frequency is much lower and not well defined.
Symptoms
Initial development may be apparently normal, but symptoms usually become evident in early childhood. Early signs include developmental delay, particularly in language, motor clumsiness, and coordination problems. As it progresses, progressive intellectual disability, hyperactivity or behavioral alterations, recurrent respiratory or ear infections, and characteristic craniofacial features that become more pronounced with age may appear. In adolescents and adults, seizures, sleep disturbances, psychomotor deterioration, scoliosis, arthritis, osteoporosis, and progressive muscle mass loss may be observed.
Disease management
Currently, there is no curative treatment or approved disease-modifying therapy for aspartylglucosaminuria. Management is based on supportive care and multidisciplinary follow-up to improve quality of life and reduce complications. It may include early intervention, educational support, speech therapy, physical therapy, and occupational therapy, in addition to standard treatment for seizures, behavioral or sleep disorders, recurrent infections, dental problems, musculoskeletal manifestations, and gastrointestinal disturbances.
Genes analyzed
Bibliography
Arvio M, Mononen I. Aspartylglycosaminuria: a review. Orphanet J Rare Dis. 2016 Dec 1;11(1):162.
Goodspeed K, Chen X, Tchan M. Aspartylglucosaminuria. 2024 Jan 18. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025.
